GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and other diabetes medications.
在JAMA Network發表的一項研究中，與使用胰島素和其他糖尿病藥物的患者相比，應用GLP-1治療的2型糖尿病患者患10種與肥胖相關的癌症的風險降低。
GLP-1 treatments, including Novo Nordisk's (NYSE:NVO) semaglutide (Wegvoy and Ozempic) and Eli Lilly And Co's (NYSE:LLY) tirzepatide (Mounjaro and Zepbound), have gained tremendous popularity.
包括諾和諾德（紐約證券交易所：NVO）的塞格列汀（Wegovy and Ozempic）和禮來（紐約證券交易所：LLY）的替西妥肽（Mounjaro and Zepbound）在內的GLP-1療法已經獲得了極大的流行。
The research examined the medical records of 1.6 million diabetes patients with no prior history of thirteen types of obesity-related cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma.
研究調查了160萬例沒有13種與肥胖相關的癌症病史的糖尿病患者的病歷，包括食管癌、結直腸癌、子宮內膜癌、膽囊癌、腎癌、肝癌、卵巢癌、胰腺癌、腦膜瘤和多發性骨髓瘤。
The study did not specify the GLP-1 medications used and analyzed data from patients prescribed GLP-1RAs, insulins, or metformin between March 2005 and November 2018.
研究沒有詳細說明GLP-1藥物的種類，並分析了在2005年3月至2018年11月期間開處GLP-1RA、胰島素或二甲雙胍的患者的數據。
Researchers found that patients using GLP-1 treatments had a significant reduction in the risk of ten cancers.
研究人員發現使用GLP-1治療的患者患10種癌症的風險顯著降低。
The authors noted this as "preliminary evidence of the potential benefit" of GLP-1 drugs in cancer prevention for high-risk populations and supported further preclinical and clinical studies to prevent certain obesity-associated cancers.
作者指出這是GLP-1藥物在預防高風險人群特定肥胖相關癌症上“潛在益處的初步證據”，並支持進一步的臨床前和臨床研究。
Novo Nordisk's kidney outcomes trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression and cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo.
諾和諾德的腎臟結局試驗通過展示8mg鹽酸塞格列汀治療者的腎臟疾病進展和心血管病和腎臟死亡的統計顯著和優越的降低達到了主要終點。
In March, the FDA approved Wegovy to reduce the risk of stroke and heart attack in overweight or obese adults without diabetes.
三月份，FDA批准Wegovy用於減少超重或肥胖成人中中風和心臟病的風險。
Eli Lilly's detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide for obstructive sleep apnea achieved all primary and key secondary endpoints for both the efficacy and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index.
禮來關於治療阻塞性睡眠呼吸暫停的替西妥肽的SURMOUNt-OSA第三期試驗的詳細結果達到了所有效力和治療方案的主要和關鍵次要終點，並在呼吸暫停低通氣指數上表現出高達62.8%的平均降低。
- ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential.
- ETF大規模押注減肥藥概念，但行業觀察人士懷疑其長期潛力。
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
譯文內容由第三人軟體翻譯。